Efficacy Study of Nivolumab Compared to Ipilimumab in Prevention of Recurrence of Melanoma After Complete Resection of Stage IIIb/c or Stage IV Melanoma (CheckMate 238)
A Phase 3, Randomized, Double-blind Study of Adjuvant Immunotherapy With Nivolumab Versus Ipilimumab After Complete Resection of Stage IIIb/c or Stage IV Melanoma in Subjects Who Are at High Risk for Recurrence (CheckMate 238: CHECKpoint Pathway and nivoluMAb Clinical Trial Evaluation 238)
Sponsor: Bristol-Myers Squibb
This PHASE3 trial investigates Melanoma and is currently completed. Bristol-Myers Squibb leads this study, which shows 25 recorded versions since 2015 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Status Flow
Change History
25 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE3
-
May 2025 — Sep 2025 [monthly]
Completed PHASE3
-
Jan 2025 — May 2025 [monthly]
Completed PHASE3
Status: Active Not Recruiting → Completed
-
Nov 2024 — Jan 2025 [monthly]
Active Not Recruiting PHASE3
-
Sep 2024 — Nov 2024 [monthly]
Active Not Recruiting PHASE3
▶ Show 20 earlier versions
-
Jul 2024 — Sep 2024 [monthly]
Active Not Recruiting PHASE3
-
Feb 2024 — Jul 2024 [monthly]
Active Not Recruiting PHASE3
-
Nov 2023 — Feb 2024 [monthly]
Active Not Recruiting PHASE3
-
Jun 2023 — Nov 2023 [monthly]
Active Not Recruiting PHASE3
-
May 2023 — Jun 2023 [monthly]
Active Not Recruiting PHASE3
-
Feb 2023 — May 2023 [monthly]
Active Not Recruiting PHASE3
-
Sep 2022 — Feb 2023 [monthly]
Active Not Recruiting PHASE3
-
May 2022 — Sep 2022 [monthly]
Active Not Recruiting PHASE3
-
Sep 2021 — May 2022 [monthly]
Active Not Recruiting PHASE3
-
Jan 2021 — Sep 2021 [monthly]
Active Not Recruiting PHASE3
-
Dec 2020 — Jan 2021 [monthly]
Active Not Recruiting PHASE3
-
Dec 2019 — Dec 2020 [monthly]
Active Not Recruiting PHASE3
-
Feb 2019 — Dec 2019 [monthly]
Active Not Recruiting PHASE3
-
Aug 2018 — Feb 2019 [monthly]
Active Not Recruiting PHASE3
-
Jul 2018 — Aug 2018 [monthly]
Active Not Recruiting PHASE3
-
Jun 2018 — Jul 2018 [monthly]
Active Not Recruiting PHASE3
-
Dec 2017 — Jun 2018 [monthly]
Active Not Recruiting PHASE3
-
Oct 2017 — Dec 2017 [monthly]
Active Not Recruiting PHASE3
-
Feb 2017 — Oct 2017 [monthly]
Active Not Recruiting PHASE3
-
Jan 2017 — Feb 2017 [monthly]
Active Not Recruiting PHASE3
First recorded
Mar 2015
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Bristol-Myers Squibb
- Ono Pharmaceutical Co. Ltd
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Adelaide, Australia , Allentown, United States , Amsterdam, Netherlands , Ann Arbor, United States , Athens, Greece , Atlanta, United States , Aurora, United States , Barcelona, Spain , Bergamo, Italy , Bergen, Norway and 115 more locations